Company profile

Intrexon

Intrexon has raised $709 million across multiple funding rounds, with notable raises including $450K Post-IPO in Feb 2015 and two additional $4.25M Post-IPO rounds in 2016. Founded in 1998, the company focuses on developing gene-based therapeutics for oncology, cardiology, and neurological disorders. With strong backing from Third Security and other strategic investors, funding has supported its R&D programs, gene-therapy platforms, and clinical pipelines. Intrexon’s investments have enabled expansion into synthetic biology, advanced genetic engineering, and precision medicine as it continues exploring next-generation human therapeutics.

Back to profiles

Quick facts

Total funding: $709 million
Founded: 1998

Reach buyers like Intrexon on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like Intrexon
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like Intrexon.

The 14-day trial ships every feature, no card required.

Start free →